Altasciences Featured Content

  1. Streamlining Study Start-Up For Accelerated Drug Development 2/20/2024

    What is the secret to safely expediting study start-ups? Explore our case study to find out how open dialogue, aligned expectations, and direct communication between Altasciences’ team leads and sponsor contributed to a clinical trial start-up of only 3.5 weeks.

  2. Flexibility In Phase I Study Timing 1/26/2024

    Combining certain Phase 2 studies with the Phase 1 protocol gives you earlier access to data, enabling more informed go/no-go decisions early in the program. This strategy makes it possible to accelerate drug development and better allocate resources.

  3. Why To Conduct Early-Phase Clinical Research In Canada 7/5/2023

    By completing your trials in Canada, you can accelerate your early phase clinical research by six to nine weeks compared to an IND submission in the U.S.

  4. Shortening Drug Development Timelines With Asian Ethnobridging Trials 1/26/2024

    Discover how ethnobridging streamlines the approval process in Asian markets and addresses potential disparities in drug metabolism between Asian and non-Asian populations.

  5. The Importance Of Diversity In Clinical Trials 10/16/2024

    A recent FDA draft guidance aims to address health disparities and enhance data quality with action plans for greater inclusivity in clinical trials. Explore practical steps to building trust and inclusivity in clinical research.

  6. First-In-Human Solution For Small And Large Molecules 3/21/2024

    Choosing the right CRO/CDMO for your first-in-human (FIH) trials enables you to run a successful study that generates high-quality data with speed and ease.

  7. Studying The Effects Of Drugs On Driving 1/25/2023

    For CNS drugs that need assessment of their impact on driving ability, Altasciences offers faster study start-up and lower costs with on-site driving simulators.

  8. Canadian CTA Frequently Asked Questions 2/20/2024

    This FAQ list offers clarity on pivotal aspects of your drug development journey, ensuring studies in Canada pave the way for U.S. FDA and EMA submissions.

  9. Central Nervous System (CNS) Active Drugs: Complex Considerations 1/26/2023

    In this article, we provide a detailed overview of the multiple facets you need to consider during the planning and conduct of your CNS-active drug development.

  10. The Complexities Of Early Phase Ophthalmic Drug Development 1/26/2023

    Discover how the complexity and challenges of bringing ophthalmic therapeutics to market can be mitigated by entrusting your drug development program to an integrated CRO/CDMO partner.